bioMérieux S.A. (EPA:BIM)
France
· Delayed Price · Currency is EUR 118.40
+0.80 (0.68%)
May 13, 2025, 3:45 PM CET
Revenue by Product
Fiscal year is January - December.
Year Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
|---|---|---|---|---|---|
| Clinical Applications | 3.10B |
Log In |
Log In |
Log In |
Log In |
| Clinical Applications Growth | 1.95% |
Log In |
Log In |
Log In |
Log In |
| Industrial Applications | 575.30M |
Log In |
Log In |
Log In |
Log In |
| Industrial Applications Growth | 4.79% |
Log In |
Log In |
Log In |
Log In |
| Clinical Applications - Microbiology | - |
Log In |
Log In |
Log In |
Log In |
| Clinical Applications - Microbiology Growth | - |
Log In |
Log In |
Log In |
Log In |
| Clinical Applications - Molecular Biology | - |
Log In |
Log In |
Log In |
Log In |
| Clinical Applications - Molecular Biology Growth | - |
Log In |
Log In |
Log In |
Log In |
| Clinical Applications - Immunoessais | - |
Log In |
Log In |
Log In |
Log In |
| Clinical Applications - Immunoessais Growth | - |
Log In |
Log In |
Log In |
Log In |
| Clinical Applications - Other Ranges | - |
Log In |
Log In |
Log In |
Log In |
| Clinical Applications - Other Ranges Growth | - |
Log In |
Log In |
Log In |
Log In |
Revenue by Geography
Fiscal year is January - December.
Year Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
|---|---|---|---|---|---|
| Americas | 1.85B |
Log In |
Log In |
Log In |
Log In |
| Americas Growth | 0.26% |
Log In |
Log In |
Log In |
Log In |
| EMEA | 964.80M |
Log In |
Log In |
Log In |
Log In |
| EMEA Growth | 7.05% |
Log In |
Log In |
Log In |
Log In |
| Asia Pacific | 637.70M |
Log In |
Log In |
Log In |
Log In |
| Asia Pacific Growth | 2.15% |
Log In |
Log In |
Log In |
Log In |
| France | 225.50M |
Log In |
Log In |
Log In |
Log In |
| France Growth | 2.64% |
Log In |
Log In |
Log In |
Log In |
| Corporate | 900.00K |
Log In |
Log In |
Log In |
Log In |
| Corporate Growth | -65.38% |
Log In |
Log In |
Log In |
Log In |